The Wall Street Journal Cancer reporters sit at the intersection of medicine, money, and policy. Pitching them is not health-blog outreach — it is business journalism with a clinical spine.

This guide gives you the editorial logic, angles, and outreach mechanics to earn coverage from one of the hardest rooms in media to enter.

WSJ treats cancer as an industry story as often as a science story. The hook is rarely "new drug works" — it's cost, access, reimbursement, market dynamics, or a corporate strategy shift.

Expect appetite for: drug pricing and PBM behavior, FDA approval economics, Medicare Part B and D implications, oncology M&A, AI in diagnostics, clinical trial access disparities, and employer benefit design.

Lifestyle and patient-experience stories exist, but they need a hard financial or policy toggle. Pure awareness content is a non-starter unless it carries a systemic "so what."

Our directory tracks 2+ active journalists on this beat, including representative bylines such as Lizeth Beltran and Stefanie Ilgenfritz. Treat this as a starting map, not a fixed roster.

Distinguish between reporters and editors before you pitch. Reporters want data and access; editors want scope, trend confirmation, and enterprise relevance.

Build your own annotated version of the The Wall Street Journal Cancer reporters list — note recent bylines, stated beats, and whether each name files short news or long enterprise.

Monitor byline velocity monthly. A reporter who published two oncology-cost stories in six weeks is materially more receptive than one who last filed on hospital consolidation.

Map adjacent beats too — pharma, health policy, and biotech desks frequently co-byline cancer coverage. Cross-beat overlap is where most successful pitches land.

The Wall Street Journal Cancer journalists respond to proprietary numbers, not press-release adjectives. A single exclusive dataset outperforms three pages of positioning.

High-conversion angles: cost-per-patient trends, payer denial rates for oncology drugs, trial enrollment by geography, pricing spread between the U.S. and EU, and post-merger R&D pipeline changes.

Offer a named, quotable executive plus an independent expert. Reporters need a protagonist and a skeptic — hand them both and you compress their reporting time.

Timing matters more than most PRs admit. Anchor pitches to earnings, FDA PDUFA dates, ASCO/AACR data drops, and CMS rule cycles.

Precision beats volume. One well-researched send to the right reporter outperforms fifty to the The Wall Street Journal Cancer journalists contacts on your list.

Use direct email where verified; use the newsroom switchboard or LinkedIn only when a named contact is stale. Never pitch a WSJ reporter through a PR platform distribution feed.

Keep subject lines factual and specific: "Data: oncology drug denial rates rose 18% in 2024" beats "Story idea for your consideration."

Respect the embargo contract absolutely. Breaking an agreed exclusivity with a WSJ reporter is a permanent relationship loss, not a temporary setback.

Log every interaction in your The Wall Street Journal Cancer reporters list — date, angle, response, and next trigger. Institutional memory is the compounding asset.

Run this before you hit send. Each line should be answerable in one sentence.

• Is the hook financial or policy-driven? If not, reframe or hold.
• Do you have exclusive data or access? State it in the first line.
• Are sources named and independent? Exec + clinician + patient.
• Is the pitch under 150 words? Cut the throat-clearing.
• Is the timing tied to a market or regulatory event?
• Have you checked the target's last three bylines?
• Is exclusivity clearly defined and time-boxed?

Pitch the story they would write, not the story you want told. That single discipline separates the pitches that get replies from the ones that get archived.